Conjugated Estrogens Pharma Grade API is supplied as a white to light buff powder intended for the manufacture of oral tablets, capsules, granules, and sterile injectable dosage forms. The substance is a purified mixture of sodium sulfate esters of estrogenic substances, primarily sodium estrone sulfate and sodium equilin sulfate, with additional minor sulfated estrogens controlled by the USP Conjugated Estrogens monograph. As a compendial active pharmaceutical ingredient, it is not a single molecular entity; batch release therefore depends on both total estrogen content and the ratio of the two principal components. Sodium estrone sulfate has a molecular weight of 372.44 g/mol as the sodium salt, and sodium equilin sulfate has a molecular weight of 370.42 g/mol. The oral grade is non-sterile and requires microbial limits per USP <1111>, while the injectable grade is supplied as a sterile powder or is subsequently sterilized before aseptic fill. If a purchaser’s qualification system requires a proprietary product code, the code is assigned by the vendor; the compendial name and grade remain the primary specification identifiers.

In manufacturing, the API is handled as a high-potency low-dose material. Tablet strengths commonly fall between 0.3 mg and 1.25 mg, so content uniformity testing under USP <905> becomes critical. Particle size, bulk density, and the order of addition are tighter variables than with higher-dose estrogens. A pre-blend with lactose monohydrate at a 1:5 to 1:10 mass ratio is typical before main blending. The API is hygroscopic; open handling time should be limited to less than 2 h at 60% relative humidity to avoid moisture uptake and sulfate ester hydrolysis.

What compendial release limits apply to oral and injectable conjugated estrogen APIs?

Release limits for conjugated estrogens are not reducible to a single assay. The USP monograph controls the sum of sodium estrone sulfate and sodium equilin sulfate to 73.0–95.0% of total conjugated estrogens and fixes the sodium equilin sulfate-to-sodium estrone sulfate ratio at 0.35–0.65. Additional sulfated estrogens are limited individually by the composition test to prevent disproportionate amounts of minor equine-specific components. Because the product is a mixture, a batch with acceptable total estrogen content can still fail if the ratio shifts outside the compendial window. This ratio is the primary difference between natural-source conjugated estrogens and synthetic single-entity estrogens in batch release.

For injectable grade, USP <85> bacterial endotoxin testing and USP <71> sterility testing are added to the release panel. Residual moisture is measured by USP <921>; the sterile grade is typically controlled to NMT 0.5% w/w to reduce hydrolysis risk during storage. Residual solvent levels follow USP <467> and ICH Q3C. Elemental impurities follow ICH Q3D and are quantified by USP <232>/<233>. The oral grade is released with microbial enumeration limits per USP <61> and USP <62>, while the injectable grade requires validated endotoxin and sterility release data.

For tablet and capsule manufacturing, the dominant failure mode is content uniformity drift during low-dose blending. A 0.625 mg conjugated estrogens tablet requires an acceptance value not more than 15.0 under USP <905>. To meet this, the API is typically pre-blended with lactose monohydrate passed through a 500 µm screen, then diluted in a bin blender. Blend uniformity is monitored by sampling at multiple positions; a relative standard deviation above 5.0% after pre-blending indicates that geometric dilution was incomplete. Direct compression formulations usually require a milled API with a D90 below 30 µm to avoid segregation at low mass fractions.

Low-dose oral solid blending and compression parameters

In low-dose oral solid manufacturing, the order of addition is more important than total mixing time. A production-scale bin blender at 60% fill volume and 12 rpm typically reaches a blend uniformity plateau after 10–15 min for a 1:10 pre-blend. Extended mixing beyond 20 min can increase fines generation from brittle excipients and does not improve content uniformity. Tablet compression on rotary presses requires forced feeders; hopper level is maintained above 40% of the feed frame capacity because low hopper level contributes to particle size segregation of a low-mass-fraction API. Weight variation for a 0.625 mg strength is not a sufficient surrogate for content uniformity; individual assay testing under USP <905> is required.

Wet granulation is used when the formulation contains microcrystalline cellulose and croscarmellose sodium. Aqueous binder systems are acceptable if the granulation pH remains between 6.0 and 8.0. Below pH 4.0, the sulfate ester linkage undergoes acid-catalyzed hydrolysis, producing free estrone and equilin and reducing assayable conjugated content. Above pH 9.0, alkaline hydrolysis also accelerates. The granulation endpoint is therefore confirmed by pH measurement rather than by visual appearance alone. Capsule filling presents a different control problem because the powder mixture must flow through a dosator or tamping pin without agglomeration. The water-soluble sodium sulfate ester absorbs moisture quickly; production areas above 60% relative humidity can cause powder bridging. Preconditioning the API to 20–25 °C and 30–40% RH for 24 h before dispensing reduces moisture uptake. Hard gelatin capsule shells are compatible, but the fill mass for a 0.3 mg capsule may be only 100–150 mg, so precise low-dose metering is required.

For granule-based oral dosage forms, the API is dissolved or suspended in aqueous binder systems when a wet granulation process is selected. Granule particle size distribution is controlled by screen aperture and impeller speed rather than by API quantity alone. If a fluid-bed granulator is used, inlet air temperature is commonly held at 40–60 °C, but product temperature should not exceed 40 °C for more than 30 min because the sulfate ester is heat-sensitive in the presence of free moisture. Drying end-point is confirmed by loss on drying, not by fixed time. Granule-based sachets and oral suspensions require final blend flow and bulk density recorded because the API mass fraction in a 1 g granule dose may be below 0.1% w/w; segregation control relies on particle size overlap between API and excipient. Published data for the hydrolytic half-life of conjugated estrogens in tablet matrices are limited; manufacturers use stress testing under 40 °C/75% RH per ICH Q1A to establish shelf life.

When the same API is assigned to a sterile injectable line

Injectable conjugated estrogen formulations use the same sodium sulfate ester mixture but impose additional particulate and endotoxin controls. The API is dissolved in Water for Injection at the compounding stage, and the resulting solution is filtered through 0.22 µm membrane filters before aseptic filling. Sterile API can be prepared by dry heat or gamma irradiation; the sterilization cycle is validated to a sterility assurance level of 10⁻⁶ according to ISO 11137 or ISO 20857. Terminal sterilization of the finished solution is avoided if the formulation is not thermally stable, so the API vendor must demonstrate a pre-sterilization bioburden below the filter validation level. Reconstitution of a lyophilized or powder-filled vial is typically controlled to a final pH near 7.0 because both acidic and strongly alkaline conditions hydrolyze the sulfate conjugates. Particulate matter in the finished injection is tested according to USP <788>; subvisible particle counts for containers ≤ 100 mL are limited to not more than 6000 particles per container at ≥10 µm and 600 particles per container at ≥25 µm for the light obscuration method.

Bacterial endotoxins for injectable conjugated estrogens are not automatically set to a generic 0.5 EU/mg; the limit must be derived from the maximum adult dose per hour per USP <85>. If the intended dose is 25 mg, an API endotoxin limit of 0.5 EU/mg would contribute 12.5 EU, which is below the 5.0 EU/kg per hour threshold for a 70 kg adult. Manufacturers nonetheless apply tighter internal limits because reconstitution and handling can add endotoxin outside the API itself. Aseptic manipulation of injectable API occurs in an ISO 14644-1 class 5 environment with unidirectional airflow. The API packaging is double LDPE with a foil outer laminate; seal integrity testing per ASTM F2096 must demonstrate no bubbles at 10–15 psi after sealing.

Injectable compounding uses Water for Injection at 15–25 °C with gentle agitation. Vigorous mixing with a high-shear rotor-stator mixer should be avoided because air entrainment and local pH extremes can increase subvisible particle formation. The solution is filtered through a 0.45 µm prefilter followed by a 0.22 µm sterilizing filter. Filter compatibility is evaluated per PDA Technical Report 26; published data for this specific API-filter combination are limited. If lyophilization is used, the cake is frozen at −40 °C and primary drying is conducted below the collapse temperature; the exact thermal cycle is product-specific and must be validated by freeze-drying microscopy.

The sulfate ester form alters aqueous processing and degradation boundaries

Conjugated estrogens differ from estradiol hemihydrate and single-entity synthetic estrogens in both molecular form and formulation behavior. Conjugated estrogens are sodium salts of sulfate esters and are freely soluble in water; estradiol hemihydrate is practically insoluble in water, requiring micronization, co-solvents, or solid dispersion for oral solid dose. This solubility difference means conjugated estrogens can be wet-granulated with aqueous binder and can be lyophilized for injection, whereas estradiol hemihydrate often requires dry granulation or alcohol-based granulation. The pharmacopoeial assay is also different: conjugated estrogens are quantified as a mixture by liquid chromatography with multiple component peaks, while estradiol hemihydrate is quantified as a single peak against a reference standard.

The clinical and metabolic distinction is that conjugated estrogens act as sulfate ester prodrugs; free estrogens are released after systemic hydrolysis. Estradiol hemihydrate is active as the parent molecule. This difference does not change the compendial chemical assay but affects dissolution and bioequivalence study design. A tablet containing 0.625 mg conjugated estrogens is not equivalent to 0.625 mg estradiol hemihydrate; the dose masses are not directly interchangeable because the molecular weights and free estrogen equivalents differ. Compared with ethinyl estradiol, conjugated estrogens are not 17α-alkylated, so the molecular class is distinct, and compendial handling is driven by mixture composition rather than single-peak purity.

Compared with synthetic conjugated estrogens, a natural-source API may contain additional minor equine estrogen sulfates that affect the chromatographic profile but remain within the same compendial limits. A synthetic mixture can be manufactured with more consistent minor-component distribution, but it must still meet the 0.35–0.65 equilin-to-estrone ratio. Batch-to-batch variance in natural-source material is controlled by blending lots before release; this blending step is not required for single-entity estradiol hemihydrate. The API should be stored in tight containers at 15–25 °C, protected from light and moisture. Repeated opening of the primary container at ambient humidity above 60% can raise water activity and promote hydrolysis. The sodium sulfate ester form is incompatible with strong oxidizing agents, mineral acids, and strong alkali; cleaning after batch completion should avoid acidic or caustic detergent residues that could hydrolyze retained product. Stainless steel contact surfaces are acceptable; copper and iron salts can catalyze oxidative degradation of the estrogen ring system and should be avoided in process water.